ASCO 2019 | CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma
Nirav Niranjan Shah
• 3 Jun 2019
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses the first bispecific chimeric antigen receptor (CAR) T-cell trial for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Dr Shah tells us about the high response rates and complete remissions witnessed in patients treated in the Phase I trial (NCT03019055), which studied differing dose levels of CAR T-cell products that target both CD-19 and CD-20. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
